Article Text

Download PDFPDF
A novel mutation, Ile289Thr, in the ALAS2 gene in a family with pyridoxine responsive sideroblastic anaemia
  1. M J Percy1,
  2. R J G Cuthbert1,
  3. A May2,
  4. M F McMullin3
  1. 1Department of Haematology, Belfast City Hospital, Belfast, UK
  2. 2Department of Haematology, Cardiff University School of Medicine, Cardiff, UK
  3. 3Department of Haematology, Queen’s University, Belfast
  1. Correspondence to:
    Dr M J Percy
    Department of Haematology, Floor C, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK;melanie.percy{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

X-linked sideroblastic anaemia (XLSA; OMIM 301 300) is characterised by accumulation of inorganic iron in erythroblast mitochondria, visualised on staining as distinctive perinuclear rings. It arises from a deficiency of the erythroid specific isoenzyme of δ-aminolaevulinate synthase (ALAS2; E.C., caused mainly by mutations affecting the catalytic or substrate-binding domains.1,2 ALAS2 uses pyridoxal-5-phosphate as a cofactor to catalyse the first, rate-limiting step of erythroid haem synthesis and pyridoxine treatment can alleviate anaemia in many cases, although the response is variable and affected by factors such as mutation, age and iron load.3,4

View Full Text